Literature DB >> 20854203

HIV-1 diversity after a class switch failure.

Michael A Kolber1, Patricia Buendia, Victor Degruttola, Richard D Moore.   

Abstract

The purpose of this study is to evaluate whether the choice of a PI- or an efavirenz (EFV)-based HAART initial regimen impacts on the viral diversity after failure from a second, class-switch salvage regimen. Sequential HAART failures after a class switch were identified for which the genotypes showed evidence of signature mutations at each failure. Each second failure was required to be from a viral burden <400 RNA c/ml. Thirteen cases of sequential failure from an initial EFV-containing to a PI-containing regimen (EP), and 19 sequential failures from an initial PI-containing to an EFV-containing regimen (PE) were identified. The persistence of signature mutations from the first failure were evaluated at second failure and compared between the EP and PE groups. Phylogenetic trees were constructed for a subgroup of cases from existing genetic sequence information and branch length analysis was used to determine evidence of viral diversity between groups. For EP sequential therapy, 10 of 12 cases carried forward a key non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation in the second failure compared to 5 of 13 cases for PE sequential therapy (p = 0.041). Phylogenetic analysis demonstrated that there was more viral diversity in the PE group as compared to the EP group, consistent with the interpretation that mutations at the second failure added to an ancestral virus closer to baseline rather than to the dominant virus at first failure. The development of HIV viral diversity after multiple HAART failures is determined by the sequence in which the regimens are ordered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854203      PMCID: PMC3000642          DOI: 10.1089/aid.2010.0069

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  20 in total

1.  Characterizing classes of antiretroviral drugs by genotype.

Authors:  A S Foulkes; V DeGruttola
Journal:  Stat Med       Date:  2003-08-30       Impact factor: 2.373

2.  A K103N resistance mutation is not an absolute contraindication to adding efavirenz to a salvage regimen: a case report.

Authors:  Michael A Kolber
Journal:  AIDS       Date:  2005-08-12       Impact factor: 4.177

3.  Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Authors:  Christine E Koval; Carrie Dykes; Jiong Wang; Lisa M Demeter
Journal:  Virology       Date:  2006-06-21       Impact factor: 3.616

4.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

5.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

Authors:  J Martinez-Picado; A V Savara; L Sutton; R T D'Aquila
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Authors:  Mar Pujades-Rodríguez; Daniel O'Brien; Pierre Humblet; Alexandra Calmy
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

Review 10.  The use of resistance testing in the management of HIV-1-infected patients.

Authors:  Philip M Grant; Andrew R Zolopa
Journal:  Curr Opin HIV AIDS       Date:  2009-11       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.